2nd International Conference on Cancer Research & Immuno-Oncology

The 2nd International Conference on Cancer Research & Immuno-Oncology aims to bring together leading academic scientists, researchers, oncologists, immunologists, pharmaceutical professionals, and industry experts to exchange and share their experiences, research results, and innovations in all aspects of cancer science, precision medicine, and immunotherapy.

This global platform will focus on emerging trends in cancer diagnostics, therapeutic advancements, immuno-oncology breakthroughs, and translational medicine. Participants will gain insights into the latest research developments on CAR-T cell therapy, cancer vaccines, immune checkpoint inhibitors, tumor microenvironment, and biomarker discovery.

The conference provides an interactive environment where researchers, clinicians, and innovators can collaborate to accelerate progress in targeted treatments, personalized oncology, and combination therapies that can improve patient outcomes and survival rates.

Join us for this scientific gathering to shape the future of cancer treatment through interdisciplinary discussions, clinical trials insights, keynote lectures, workshops, and poster sessions.

Market Analysis
The global cancer therapeutics market was valued at USD 205 billion in 2024 and is expected to reach USD 375 billion by 2030, growing at a CAGR of 9.8%. This growth is driven by the rising prevalence of various cancers, the aging global population, and the rapid expansion of immunotherapy and precision oncology.

Immuno-oncology alone represents one of the fastest-growing fields, estimated to reach USD 210 billion by 2032, propelled by the success of immune checkpoint inhibitors and adoptive T-cell therapies.
Major players such as Bristol Myers Squibb, Merck & Co., Roche, AstraZeneca, and Novartis are investing heavily in next-generation cancer immunotherapies and AI-driven biomarker analysis.

The conference also addresses the economic burden of cancer—with annual treatment costs projected to surpass USD 1 trillion globally by 2035—highlighting the urgent need for innovation in early detection, cost-effective therapeutics, and healthcare accessibility.

Why to Attend
Discover groundbreaking research and emerging technologies in cancer immunotherapy and targeted medicine.
Network with global leaders from oncology, biotechnology, pharmaceuticals, and academia.
Gain insights into clinical trials, FDA regulations, and translational applications from research to patient care.
Participate in panel discussions, symposia, and poster presentations addressing future directions in cancer biology and therapy.
Access opportunities for collaboration, funding, and publication in top scientific journals.

Who Should Attend
Oncologists, Immunologists, and Haematologists
Cancer Researchers and Biomedical Scientists
Immunotherapy & Precision Medicine Experts
Radiologists, Pathologists, and Pharmacologists
Pharmaceutical & Biotechnology Industry Professionals
Academic Scholars, Postdoctoral Fellows, and Students
Clinical Researchers and Trial Coordinators
Healthcare Policymakers and Regulatory Professionals

Benefits of Participation
Networking Opportunities: Build strategic collaborations with leading cancer institutes and biotech firms.
Knowledge Expansion: Stay ahead of innovations in cancer genomics, immuno-oncology, and therapeutic design.
Brand Visibility: Showcase your research, product, or institution to a global scientific audience.
Career Growth: Enhance your professional development with certification and exposure to new research trends.
Global Recognition: Gain acknowledgment for your contribution to cancer research and patient care advancement.
Collaborative Projects: Initiate partnerships for clinical trials, grants, and translational research.